Botulinum toxin type A injection to masticatory muscles

For the treatment of

Temporomandibular disorder (TMD) and/or Masseter Hypertrophy (MH)

Commissioning position

This intervention is not commissioned and therefore should not be routinely offered to patients. Application for funding approval can be made, using the IFR process, by the clinician recommending the intervention, if their assessment is that there are exceptional reasons why their patient could benefit from it.

Summary of rationale

The evidence on clinical effectiveness of Botulinum toxin A injection for TMS or MH is currently inconclusive but adverse effects have been noted, including impaired muscle function and jawbone density loss. When studies have identified symptomatic benefit, there is a high rate of relapse by 3 months and repeat injections were found to be associated with higher rates of adverse effects than a single injection.

Associated Pathways

There are no associated pathways.

Places covered by

  • east-riding
  • hull
  • north-east-lincolnshire
  • north-lincolnshire
  • north-yorkshire
  • vale-of-york
Date created: 08/07/2025, 11:44
Last modified: 30/07/2025, 09:13
Date of review: ٣١‏/٧‏/٢٠٢٨